Additional file 1 of A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients

Additional file 1: Fig. S1. A detailed schematic of the study. Fig. S2. The mutation landscape in the two cohorts. A. The mutation landscape and clinical characteristics in patients with hematuria. B. The mutation landscape and clinical characteristics in patients with NMIBC. Table S1. Patients’ characteristics between OncoUrine positive and negative groups. Table S2. The predictive performance of OncoUrine during follow-up. Table S3. The gene list and primers of the OncoUrine panel. Table S4. The recurrence rate during follow-up in patients with false positive OncoUrine test results and with true negative results.

补充材料1：图S1。本研究的详细示意图。图S2。两个队列的突变图谱。A. 血尿患者的突变图谱与临床特征。B. 非肌层浸润性膀胱癌（Non-Muscle Invasive Bladder Cancer, NMIBC）患者的突变图谱与临床特征。表S1。OncoUrine检测阳性与阴性组患者的临床特征。表S2。随访期间OncoUrine检测的预测性能。表S3。OncoUrine检测组合的基因列表与引物。表S4。OncoUrine检测假阳性与真阴性患者随访期间的复发率。